Novartis (NVS) – Research Analysts’ Recent Ratings Changes
by Sarita Garza · The Markets DailySeveral analysts have recently updated their ratings and price targets for Novartis (NYSE: NVS):
- 9/10/2026 – Novartis was upgraded by HSBC Holdings plc from “reduce” to “hold”. They now have a $136.00 price target on the stock, up from $123.00.
- 9/10/2026 – Novartis was upgraded by HSBC Holdings plc from “reduce” to “hold”. They now have a $136.00 price target on the stock, up from $123.00.
- 9/8/2026 – Novartis was downgraded by Deutsche Bank Aktiengesellschaft from “buy” to “hold”.
- 9/8/2026 – Novartis is now covered by Royal Bank Of Canada. They set a “sector perform” rating on the stock.
- 7/24/2026 – Novartis had its “buy (b)” rating reaffirmed by Weiss Ratings.
- 7/22/2026 – Novartis had its “buy” rating reaffirmed by Citigroup Inc..
Novartis AG (NYSE: NVS) is a Switzerland-based pharmaceutical company focused on discovering, developing and commercializing innovative medicines. The company’s portfolio addresses major disease areas including cardiovascular, renal and metabolic conditions, immunology, neuroscience, oncology and hematology.
Novartis markets medicines such as Entresto for certain heart conditions, Cosentyx for inflammatory diseases, Kisqali for breast cancer, Kesimpta for multiple sclerosis, Leqvio for cholesterol management, Pluvicto for certain prostate cancers and Scemblix for chronic myeloid leukemia.